Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

Rhea-AI Summary

Immunic (Nasdaq: IMUX) will announce its financial results for Q4 and the year ended December 31, 2021, on February 24, 2022, before U.S. market opens. Following this, a webcast will be held at 8:00 am ET. The company focuses on developing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases, including multiple sclerosis and ulcerative colitis. This upcoming report may provide insights into the company's financial position and future strategy.

Positive

• Upcoming release of financial results may attract investor interest.
• Focus on innovative therapies targeting significant health issues.

Negative

• None.

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2021, including a corporate update, on Thursday, February 24, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_d6PSP8F3RCWrEcchTzfi6Q or on the "Events and Presentations" section of Immunic's website at ir.imux.com/events-and-presentations. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.

An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at ir.imux.com/events-and-presentations.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγ/RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216
immunic@rxir.com

US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-to-announce-financial-results-for-the-year-ended-december-31-2021-and-provide-corporate-update-301484523.html

SOURCE Immunic, Inc.

FAQ

When will Immunic release its financial results for 2021?

Immunic will release its financial results for the year ended December 31, 2021, on February 24, 2022.

What time is the webcast for Immunic's financial results?

The webcast will take place at 8:00 am ET on February 24, 2022.

What is the focus of Immunic's product development?

Immunic is developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases.

What diseases are targeted by Immunic's lead program IMU-838?

IMU-838 is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis.